Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ding Jun Sheng
- Development stage
- Unknown
- Lead developer
- Inner Mongolia Shuangqi Pharmaceutical
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Ding Jun Sheng is a live biotherapeutic product (LBP) consisting of viable *Lactobacillus crispatus* (strain DM89101) formulated as vaginal capsules. Developed and manufactured by Inner Mongolia Shuangqi Pharmaceutical, it is primarily indicated for the treatment of bacterial vaginosis and the restoration of healthy vaginal microecology. The drug works by colonizing the vaginal mucosa, where it produces lactic acid to maintain an acidic pH and secretes antimicrobial substances such as hydrogen peroxide and bacteriocins, thereby inhibiting the growth of pathogenic bacteria. In clinical research, Ding Jun Sheng is being evaluated for its ability to promote the clearance of high-risk human papillomavirus (HPV) infections, particularly in postmenopausal women, by improving vaginal health and local immunity. It is often studied as a monotherapy or in combination with recombinant human interferon α2b (Xin Fu Ning).
- Brand names
- Ding Jun Sheng定君生
- Other names
- Lactobacillus crispatus capsulesVaginal Lactobacillus crispatus capsulesLactobacillus crispatus DM89101Vaginal Lactobacillus Viable Capsules
02
Targets
VMB (Vaginal microbiota)
Beyond the preview
Go deeper on Ding Jun Sheng.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ding Jun Sheng.